David Goel's most recent trade in Adaptive Biotechnologies Corp was a trade of 234,295 Common Stock done at an average price of $38.2 . Disclosure was reported to the exchange on March 8, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 38.22 per share. | 08 Mar 2021 | 234,295 | 12,880,795 (10%) | 0% | 38.2 | 8,954,310 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 40.42 per share. | 08 Mar 2021 | 215,698 | 12,399,392 (9%) | 0% | 40.4 | 8,719,333 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.62 per share. | 08 Mar 2021 | 85,911 | 12,615,090 (9%) | 0% | 41.6 | 3,575,753 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.22 per share. | 08 Mar 2021 | 75,000 | 12,805,795 (10%) | 0% | 39.2 | 2,941,163 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.21 per share. | 08 Mar 2021 | 71,194 | 12,701,001 (10%) | 0% | 41.2 | 2,933,641 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.16 per share. | 08 Mar 2021 | 34,302 | 12,365,090 (9%) | 0% | 41.2 | 1,411,887 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.97 per share. | 08 Mar 2021 | 33,600 | 12,772,195 (10%) | 0% | 40.0 | 1,343,039 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 42.38 per share. | 08 Mar 2021 | 30,268 | 12,309,090 (9%) | 0% | 42.4 | 1,282,664 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 41.47 per share. | 08 Mar 2021 | 25,732 | 12,339,358 (9%) | 0% | 41.5 | 1,067,037 | Common Stock |
| Adaptive Biotechnologies Corp | David Goel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 3,759 | 3,759 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | David Goel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 1,504 | 1,504 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | David Goel | Other, See Remarks | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 20 Jul 2020 | 2,000,000 | 13,115,090 (10%) | 1% | 40 | 80,000,000 | Common Stock |